Article
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Advances in cancer research - 1 Jan 2022
Coley Alexander B, Ward Antonio, Keeton Adam B, Chen Xi, Maxuitenko Yulia, Prakash Aishwarya, Li Feng, Foote Jeremy B, Buchsbaum Donald J, Piazza Gary A
Abstract excerpt
Mutations in the three RAS oncogenes are present in approximately 30% of all human cancers that drive tumor growth and metastasis by aberrant activation of RAS-mediated signaling. Despite the well-established role of RAS in tumorigenesis, past efforts to develop small molecule inhibitors have failed for various reasons leading many to consider RAS as "undruggable." Advances over the past decade with KRAS(G12C)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.